TURGEX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TURGEX (TURGEX).

How it works

TURGEX is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin into presynaptic neurons.

What the body does with it

Metabolism	Primarily metabolized via CYP2D6 and CYP3A4 isoenzymes; also undergoes glucuronidation. Metabolites are largely inactive.
Excretion	Approximately 70% renal (60% unchanged, 10% as inactive glucuronide conjugate), 20% fecal via biliary elimination, and 10% metabolized by hepatic CYP3A4 to minor metabolites
Half-life	Terminal half-life 8.2 ± 1.5 hours; extends to 15–20 hours in moderate hepatic impairment (Child-Pugh B) and to 12–14 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment
Protein binding	92% bound, primarily to albumin; slightly reduced (85%) in hypoalbuminemia or chronic liver disease
Volume of Distribution	0.9 ± 0.2 L/kg; indicates extensive tissue distribution with partitioning into well-perfused organs; Vd increases to 1.4 L/kg in obesity
Bioavailability	Oral immediate-release: 68% ± 9% (first-pass metabolism by CYP3A4 in gut and liver); Oral extended-release: 55% ± 12% (lower due to incomplete absorption); Subcutaneous: 95% ± 5%; no IV formulation
Onset of Action	Intravenous: 2–5 minutes; Oral immediate-release: 30–60 minutes; Oral extended-release: 1–2 hours
Duration of Action	Intravenous: 6–8 hours; Oral immediate-release: 8–12 hours; Oral extended-release: 18–24 hours; clinical effect correlates with plasma concentration >0.5 mcg/mL

Classification & Brands

Dosing & administration

10 mg orally once daily

Dosage form	EMULSION
Renal impairment	GFR ≥30 mL/min: no adjustment; GFR <30 mL/min: avoid use
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce to 5 mg once daily; Child-Pugh C: contraindicated
Pediatric use	0.2 mg/kg orally once daily; maximum 10 mg/day
Geriatric use	Start at 5 mg once daily; titrate to response

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TURGEX (TURGEX).

Breastfeeding	TURGEX is excreted in human milk (M/P ratio unknown). Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment.
Teratogenic Risk	TURGEX is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and premature closure of ductus arteriosus.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS – Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to TURGEX or any of its components","Concomitant use with MAOIs or within 14 days of MAOI discontinuation","Concomitant use with linezolid or intravenous methylene blue","Uncontrolled narrow-angle glaucoma"]

Clinical Precautions

Precautions

["Clinical worsening and suicide risk","Serotonin syndrome: risk increased with co-administration of other serotonergic drugs","Activation of mania/hypomania in bipolar disorder patients","QTc prolongation: risk increased in patients with cardiac disease or electrolyte abnormalities","Seizures: use with caution in patients with seizure disorder","Angle-closure glaucoma: may cause mydriasis, trigger acute attack","Hyponatremia: especially in elderly or volume-depleted patients"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TURGEX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TURGEX (TURGEX).

How it works

TURGEX is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin into presynaptic neurons.

What the body does with it

Metabolism	Primarily metabolized via CYP2D6 and CYP3A4 isoenzymes; also undergoes glucuronidation. Metabolites are largely inactive.
Excretion	Approximately 70% renal (60% unchanged, 10% as inactive glucuronide conjugate), 20% fecal via biliary elimination, and 10% metabolized by hepatic CYP3A4 to minor metabolites
Half-life	Terminal half-life 8.2 ± 1.5 hours; extends to 15–20 hours in moderate hepatic impairment (Child-Pugh B) and to 12–14 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment
Protein binding	92% bound, primarily to albumin; slightly reduced (85%) in hypoalbuminemia or chronic liver disease
Volume of Distribution	0.9 ± 0.2 L/kg; indicates extensive tissue distribution with partitioning into well-perfused organs; Vd increases to 1.4 L/kg in obesity
Bioavailability	Oral immediate-release: 68% ± 9% (first-pass metabolism by CYP3A4 in gut and liver); Oral extended-release: 55% ± 12% (lower due to incomplete absorption); Subcutaneous: 95% ± 5%; no IV formulation
Onset of Action	Intravenous: 2–5 minutes; Oral immediate-release: 30–60 minutes; Oral extended-release: 1–2 hours
Duration of Action	Intravenous: 6–8 hours; Oral immediate-release: 8–12 hours; Oral extended-release: 18–24 hours; clinical effect correlates with plasma concentration >0.5 mcg/mL

Classification & Brands

Dosing & administration

10 mg orally once daily

Dosage form	EMULSION
Renal impairment	GFR ≥30 mL/min: no adjustment; GFR <30 mL/min: avoid use
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce to 5 mg once daily; Child-Pugh C: contraindicated
Pediatric use	0.2 mg/kg orally once daily; maximum 10 mg/day
Geriatric use	Start at 5 mg once daily; titrate to response

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TURGEX (TURGEX).

Breastfeeding	TURGEX is excreted in human milk (M/P ratio unknown). Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment.
Teratogenic Risk	TURGEX is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and premature closure of ductus arteriosus.
Fetal Monitoring